<DOC>
	<DOCNO>NCT00468936</DOCNO>
	<brief_summary>Stable heart transplant patient Mycophenolate Mofetil ( MMF ) sign screen consent form order evaluate gastrointestinal symptom rating scale ( GSRS ) questionnaire . Those score three least two question eligible study . Once sign study consent randomize one two arm . It think severity GI side effect reduce time patient Myfortic arm versus severity GI side effect time patient remain MMF treatment . Patients evaluate GSRS , The Psychological Well-Being Schedule , IT01/02 Checklist evaluation GI symptom follow one year ( visit 1 month , 3 month , 6 month , 12 month ) .</brief_summary>
	<brief_title>Myfortic Heart Transplant Patients With Gastrointestinal ( GI ) Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Stable dose MMF least 4 week Over 18 year age Heart transplant least three month prior study GI symptom know caused MPA therapy Acute rejection episode past 4 week History malignancy since transplant Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>anti-rejection</keyword>
	<keyword>GI side effect</keyword>
	<keyword>heart transplant patient</keyword>
</DOC>